**S1 Table 5. Detailed effectiveness and drug cost assumptions for systolic BP (age, sex, BP interval). Effects reported in this table reflect 75% adherence to medications.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Men** |   |   |   |   |   |   |   |
|  | Stage 1 (140-159 mm Hg) |  | Stage 2 ( ≥ 160 mm Hg) |
|  |  |  |  |  |  |  |  |
| **Systolic BP interval** | 140-145 | 146-148 | 149-159 |  | 160-169 | 170-179 | >=180 |
| **Number of standard dose drugs** | 0.5 | 1.0 | 2.0 |  | 3.0 | 3.5 | 4.0 |
| **35-44 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 41.1% | 20.0% | 25.4% |  | 7.6% | 1.5% | 4.4% |
| **percent of stage** | 47.5% | 23.1% | 29.4% |  | 56.2% | 11.0% | 32.8% |
| **BP change after treatment** | 4.2 | 8.4 | 18.2 |  | 27.6 | 36.6 | 42.0 |
| **RR CHD after treatment** | 0.89 | 0.79 | 0.61 |  | 0.47 | 0.37 | 0.32 |
| **RR stroke after treatment** | 0.86 | 0.75 | 0.53 |  | 0.38 | 0.28 | 0.23 |
| **Annual anti-HT medication cost** |  ¥ 33.68  |  ¥ 67.36  |  ¥ 124.13  |  |  ¥ 184.52  |  ¥ 246.60  |  ¥ 269.43  |
| **45-54 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 35.3% | 16.3% | 25.4% |  | 10.1% | 4.3% | 8.6% |
| **percent of stage** | 45.8% | 21.2% | 33.0% |  | 44.0% | 18.8% | 37.2% |
| **BP change after treatment** | 4.2 | 8.4 | 18.2 |  | 27.6 | 36.6 | 42.0 |
| **RR CHD after treatment** | 0.89 | 0.80 | 0.61 |  | 0.47 | 0.37 | 0.32 |
| **RR stroke after treatment** | 0.86 | 0.75 | 0.53 |  | 0.38 | 0.28 | 0.23 |
| **Annual anti-HT medication cost** |  ¥ 33.68  |  ¥ 67.36  |  ¥ 124.13  |  |  ¥ 184.52  |  ¥246.60  |  ¥ 269.43  |
| **55-64 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 20.6% | 18.2% | 25.9% |  | 16.2% | 9.1% | 9.9% |
| **percent of stage** | 31.8% | 28.2% | 40.0% |  | 45.9% | 25.9% | 28.2% |
| **BP change after treatment** | 4.2 | 8.4 | 18.2 |  | 27.6 | 36.6 | 42.0 |
| **RR CHD after treatment** | 0.90 | 0.81 | 0.63 |  | 0.49 | 0.39 | 0.34 |
| **RR stroke after treatment** | 0.88 | 0.78 | 0.58 |  | 0.44 | 0.34 | 0.29 |
| **Annual anti-HT medication cost** |  ¥ 33.68  |  ¥ 67.36  |  ¥ 124.13  |  |  ¥ 184.52  |  ¥246.60  |  ¥ 269.43  |
|  |  |  |  |  |  |  |  |
| **65-74 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 23.0% | 9.4% | 29.0% |  | 14.6% | 7.7% | 16.3% |
| **percent of stage** | 0.0% | 0.0% | 47.2% |  | 37.9% | 19.9% | 42.1% |
| **BP change after treatment** | 0.0 | 0.0 | 8.4 |  | 18.2 | 27.6 | 36.6 |
| **RR CHD after treatment** | 1.00 | 1.00 | 0.85 |  | 0.71 | 0.59 | 0.50 |
| **RR stroke after treatment** | 1.00 | 1.00 | 0.81 |  | 0.63 | 0.50 | 0.40 |
| **Annual anti-HT medication cost** |  ¥ -  |  ¥ -  |  ¥ 67.36  |  |  ¥ 124.13  |  ¥ 184.52  |  ¥ 246.60  |
| **75-84 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 26.4% | 9.1% | 29.0% |  | 13.2% | 12.2% | 10.1% |
| **percent of stage** | 0.0% | 0.0% | 44.9% |  | 37.1% | 34.4% | 28.5% |
| **BP change after treatment** | 0.0 | 0.0 | 8.4 |  | 18.2 | 27.6 | 36.6 |
| **RR CHD after treatment** | 1.00 | 1.00 | 0.89 |  | 0.77 | 0.68 | 0.60 |
| **RR stroke after treatment** | 1.00 | 1.00 | 0.87 |  | 0.74 | 0.63 | 0.55 |
| **Annual anti-HT medication cost** |  ¥ -  |  ¥ -  |  ¥ 67.36  |  |  ¥ 124.13  |  ¥ 184.52  |  ¥ 246.60 |
| **Women** |   |   |   |   |   |   |   |
|  | Stage 1 (140-159 mm Hg) |  | Stage 2 ( ≥ 160 mm Hg) |
| **Systolic BP interval** | 140-145 | 146-148 | 149-159 |  | 160-169 | 170-179 | >=180 |
|  |   |   |   |  |   |   |   |
| **Number of standard dose drugs** | 0.5 | 1.0 | 2.0 |  | 3.0 | 3.5 | 4.0 |
| **35-44 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 40.0% | 12.8% | 24.5% |  | 14.4% | 3.6% | 4.7% |
| **percent of stage** | 51.8% | 16.5% | 31.7% |  | 63.6% | 15.8% | 20.7% |
| **BP change after treatment** | 4.2 | 8.4 | 18.2 |  | 27.6 | 36.6 | 42.0 |
| **RR CHD after treatment** | 0.89 | 0.80 | 0.61 |  | 0.47 | 0.37 | 0.32 |
| **RR stroke after treatment** | 0.86 | 0.74 | 0.52 |  | 0.37 | 0.27 | 0.22 |
| **Annual anti-HT medication cost** |  ¥ 33.68  |  ¥ 67.36  |  ¥ 124.13  |  |  ¥ 184.52  |  ¥ 246.60  |  ¥ 269.43  |
|  |  |  |  |  |  |  |  |
| **45-54 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 25.1% | 16.0% | 26.5% |  | 14.6% | 7.5% | 10.3% |
| **percent of stage** | 37.1% | 23.7% | 39.2% |  | 45.1% | 23.0% | 31.9% |
| **BP change after treatment** | 4.2 | 8.4 | 18.2 |  | 27.6 | 36.6 | 42.0 |
| **RR CHD after treatment** | 0.90 | 0.82 | 0.65 |  | 0.52 | 0.42 | 0.37 |
| **RR stroke after treatment** | 0.88 | 0.77 | 0.57 |  | 0.42 | 0.32 | 0.27 |
| **Annual anti-HT medication cost** |  ¥ 33.68  |  ¥ 67.36  |  ¥ 124.13  |  |  ¥ 184.52  |  ¥ 246.60  |  ¥ 269.43  |
|  |  |  |  |  |  |  |  |
| **55-64 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 22.6% | 14.9% | 21.6% |  | 19.3% | 8.8% | 12.7% |
| **percent of stage** | 38.2% | 25.2% | 36.6% |  | 47.3% | 21.5% | 31.2% |
| **BP change after treatment** | 4.2 | 8.4 | 18.2 |  | 27.6 | 36.6 | 42.0 |
| **RR CHD after treatment** | 0.91 | 0.83 | 0.68 |  | 0.55 | 0.45 | 0.41 |
| **RR stroke after treatment** | 0.89 | 0.79 | 0.60 |  | 0.46 | 0.36 | 0.31 |
| **Annual anti-HT medication cost** |  ¥ 33.68  |  ¥ 67.36  |  ¥ 124.13  |  |  ¥ 184.52  |  ¥ 246.60  |  ¥ 269.43  |
|  |  |  |  |  |  |  |  |
| **65-74 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 18.5% | 16.5% | 30.0% |  | 19.1% | 6.0% | 9.8% |
| **percent of stage** | 0.0% | 0.0% | 46.2% |  | 54.6% | 17.3% | 28.1% |
| **BP change after treatment** | 0.0 | 0.0 | 8.4 |  | 18.2 | 27.6 | 36.6 |
| **RR CHD after treatment** | 1.00 | 1.00 | 0.86 |  | 0.72 | 0.61 | 0.52 |
| **RR stroke after treatment** | 1.00 | 1.00 | 0.82 |  | 0.65 | 0.52 | 0.42 |
| **Annual anti-HT medication cost** |  ¥ -  |  ¥ -  |  ¥ 67.36  |  |  ¥ 124.13  |  ¥ 184.52  |  ¥ 246.60  |
|  |  |  |  |  |  |  |  |
| **75-84 years** |   |   |   |   |   |   |   |
| **percent of all untreated HT** | 18.3% | 12.6% | 26.6% |  | 16.5% | 12.9% | 13.1% |
| **percent of stage** | 0.0% | 0.0% | 46.3% |  | 38.8% | 30.4% | 30.8% |
| **BP change after treatment** | 0.0 | 0.0 | 8.4 |  | 18.2 | 27.6 | 36.6 |
| **RR CHD after treatment** | 1.00 | 1.00 | 0.90 |  | 0.79 | 0.70 | 0.62 |
| **RR stroke after treatment** | 1.00 | 1.00 | 0.89 |  | 0.77 | 0.67 | 0.59 |
| **Annual anti-HT medication cost** |  ¥ -  |  ¥ -  |  ¥ 67.36  |  |  ¥ 124.13  |  ¥ 184.52  |  ¥ 246.60  |
|  |   |   |   |   |   |   |   |